Suppressor of Tumorigenicity 3 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ST3 MCID: SPP010 MIFTS: 57	Suppressor of Tumorigenicity 3 (ST3) Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 ⁵⁷ ⁷³

Cervical Carcinoma ⁵⁷ ⁵⁵

Cervical Carcinoma, Tumor-Suppressor Gene Involved in; Ccts ⁵⁷

Cervical Carcinoma, Tumor-Suppressor Gene Involved in ⁵⁷

Tumor-Suppressor Gene, Hela Cell Type; Tshl ⁵⁷

Tumor-Suppressor Gene, Hela Cell Type ⁵⁷

Cervix Carcinoma ⁷³

Tshl ⁵⁷

Ccts ⁵⁷

St3 ⁵⁷

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM ⁵⁷ 191181

UMLS ⁷³ C1860658 C0302592

Sources

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary : Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to adenocarcinoma and retinoblastoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cell Cycle, Mitotic. The drugs Nolvadex and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Description from OMIM: 191181

Sources

Related Diseases for Suppressor of Tumorigenicity 3

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	30.0	TP53 RB1 MYC CDKN2A
2	retinoblastoma	29.9	TP53 RB1 CDKN2A CDKN1A
3	cervix carcinoma	29.8	TP53 FHIT CDKN2A
4	small cell cancer of the lung	29.8	TP53 RB1 MYC CDKN2A
5	cervical adenocarcinoma	29.8	TP53 CDKN2A CDKN1A
6	papilloma	29.7	UBE3A TP53 RB1 PCNA CDKN2A CDKN1A
7	anal squamous cell carcinoma	29.6	CDKN2A TP53
8	malignant mesenchymoma	29.6	TP53 FHIT CDKN1A
9	pancreas adenocarcinoma	29.5	TP53 MYC CDKN2A
10	bladder cancer	29.4	TP53 RB1 MYC CDKN2A CDKN1A
11	glioblastoma	29.2	TP53 RB1 MYC CDKN2A CDKN1A
12	basal cell carcinoma	29.0	TP53 CDKN2A CDKN1A BCL2 BAX
13	nasopharyngeal carcinoma	28.9	TP53 MYC CDKN2A CCNB1 BCL2
14	ovarian cancer	28.8	BAX BCL2 CDKN1A MYC TP53
15	endometrial cancer	28.6	TP53 RB1 MYC CDKN2A CDKN1A BCL2
16	cervical cancer	28.3	UBE3A TP53 RB1 MYC FHIT CDKN2A
17	lung cancer	28.3	TP53 TAP1 RB1 PCNA MYC FHIT
18	breast cancer	28.3	TP53 RB1 PCNA MYC FHIT CDKN1A
19	cataract 40	11.3
20	perrault syndrome 1	11.1
21	cataract, total congenital	11.1
22	cervical adenosquamous carcinoma	11.0
23	high-grade neuroendocrine carcinoma of the cervix uteri	11.0
24	cervical intraepithelial neoplasia	10.3
25	vulvar adenocarcinoma	10.3	TP53 RB1
26	tropical calcific pancreatitis	10.2
27	bladder squamous cell carcinoma	10.2	TP53 CDKN2A
28	keratinizing squamous cell carcinoma	10.2	TP53 CDKN2A
29	spitz nevus	10.2	TP53 CDKN2A
30	actinic cheilitis	10.2	TP53 CDKN1A
31	gallbladder adenoma	10.2	RB1 CDKN2A
32	bladder carcinoma in situ	10.2	TP53 CDKN2A
33	hepatic angiomyolipoma	10.2	RB1 MYC
34	bladder transitional cell papilloma	10.2	TP53 CDKN1A
35	invasive bladder transitional cell carcinoma	10.2	TP53 CDKN1A
36	scrotal carcinoma	10.2	TP53 CDKN2A
37	vulva squamous cell carcinoma	10.2	TP53 CDKN2A
38	atypical follicular adenoma	10.2	TP53 CDKN1A
39	nasal cavity adenocarcinoma	10.2	CDKN2A TP53
40	vulvar disease	10.2	TP53 CDKN2A
41	lip cancer	10.2	TP53 CDKN1A
42	bartholin's gland disease	10.2	CDKN2A TP53
43	high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement	10.2	MYC BCL2
44	diffuse large b-cell lymphoma of the central nervous system	10.2	MYC BCL2
45	hypoxia	10.2
46	periosteal chondrosarcoma	10.2	CDKN2A RB1
47	b cell prolymphocytic leukemia	10.2	MYC TP53
48	glycogen-rich clear cell breast carcinoma	10.2	CDKN2A TP53
49	chronic venous leg ulcers	10.2	MYC BCL2
50	barrett's adenocarcinoma	10.2	TP53 FHIT CDKN2A

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:

Sources

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM:

191181

GenomeRNAi Phenotypes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

²⁶ (show all 35)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	10.63	RB1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-106	10.63	BCL2
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-108	10.63	CDKN1A
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-118	10.63	CCNB1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	10.63	BCL2
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10.63	CCNB1 RB1
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	10.63	BCL2
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-147	10.63	RB1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-159	10.63	BCL2
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	10.63	UBE3A
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-172	10.63	RB1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.63	RB1 BCL2
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	10.63	CCNB1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-188	10.63	CCNB1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-194	10.63	BCL2
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	10.63	CCNB1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	10.63	BCL2
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-2	10.63	UBE3A
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	10.63	CCNB1 RB1 BCL2
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	10.63	CDKN1A
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-37	10.63	BCL2
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-39	10.63	CDKN1A
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.63	UBE3A
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.63	CCNB1 RB1
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	10.63	CCNB1 CDKN1A RB1 UBE3A
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.63	RB1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	10.63	UBE3A BCL2
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-76	10.63	CDKN1A
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.63	BCL2
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-88	10.63	CDKN1A BCL2
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	10.63	CCNB1
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-96	10.63	BCL2
33	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.78	BAX BCL2 CDKN1A CDKN2A PCNA RB1
34	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.78	BAX BCL2 CDKN1A CDKN2A PCNA RB1
35	Increased viability with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.43	BAX BCL2 CCNB1 CDKN1A PCNA TP53

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

⁴⁶ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.18	BAX BCL2 CDKN1A CDKN2A MYC PCNA
2	hematopoietic system	MP:0005397	10.18	BAX BCL2 CDKN1A CDKN2A FHIT MYC
3	growth/size/body region	MP:0005378	10.16	BAX BCL2 CDKN1A CDKN2A MYC PCNA
4	immune system	MP:0005387	10.16	BAX BCL2 CDKN1A CDKN2A FHIT MYC
5	behavior/neurological	MP:0005386	10.15	BAX BCL2 CDKN1A CDKN2A MYC RB1
6	mortality/aging	MP:0010768	10.14	BAX BCL2 CDKN1A CDKN2A FHIT MYC
7	integument	MP:0010771	10.09	BCL2 CDKN1A CDKN2A FHIT MYC RB1
8	digestive/alimentary	MP:0005381	10.08	BCL2 CDKN1A CDKN2A FHIT MYC RB1
9	adipose tissue	MP:0005375	10.03	BCL2 CDKN1A MYC PCNA RB1 TP53
10	hearing/vestibular/ear	MP:0005377	9.97	BAX BCL2 CDKN1A MYC RB1 TP53
11	neoplasm	MP:0002006	9.97	BAX BCL2 CDKN1A CDKN2A FHIT MYC
12	muscle	MP:0005369	9.91	BAX BCL2 CDKN1A CDKN2A MYC RB1
13	nervous system	MP:0003631	9.91	BAX BCL2 CDKN1A CDKN2A MYC RB1
14	no phenotypic analysis	MP:0003012	9.7	CDKN1A CDKN2A MYC PCNA RB1 TP53
15	pigmentation	MP:0001186	9.35	BCL2 CDKN2A MYC RB1 TP53
16	reproductive system	MP:0005389	9.28	BAX BCL2 CDKN1A CDKN2A MYC PCNA

Sources

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Nolvadex ¹⁸ ⁴⁹	TAMOXIFEN CITRATE	AstraZeneca	October 1998
FDA Label: Nolvadex Disease/s that Drug Treats:Breast Cancer Indications and Usage: ¹⁸ Metastatic Breast Cancer:NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. Inpremenopausal women with metastatic breast cancer, NOLVADEX is an alternative tooophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumorsare estrogen receptor positive are more likely to benefit from NOLVADEX therapy.Adjuvant Treatment of Breast Cancer:NOLVADEX is indicated for the treatment of node-positive breast cancer in women followingtotal mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In someNOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four ormore positive axillary nodes.NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in womenfollowing total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.The estrogen and progesterone receptor values may help to predict whether adjuvantNOLVADEX therapy is likely to be beneficial.NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvantNOLVADEX therapy for breast cancer.Ductal Carcinoma in Situ (DCIS):In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated toreduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of thelabel). The decision regarding therapy with NOLVADEX for the reduction in breast cancerincidence should be based upon an individual assessment of the benefits and risks ofNOLVADEX therapy.Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patientswith breast cancer. Reduction in Breast Cancer Incidence in High Risk Women:NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk forbreast cancer. This effect was shown in a study of 5 years planned duration with a medianfollow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. Thelonger-term effects are not known. In this study, there was no impact of tamoxifen on overall orbreast cancer-related mortality (see BOXED WARNING at the beginning of the label).NOLVADEX is indicated only for high-risk women. âHigh riskâ is defined as women at least35 years of age with a 5-year predicted risk of breast cancer â¥ 1.67%, as calculated by the GailModel.Examples of combinations of factors predicting a 5-year risk â¥ 1.67% are:Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and ahistory of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of atleast one breast biopsy; or LCISAge 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at firstlive birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 oryounger; or One first degree relative with a history of breast cancer, and a personal history of a breastbiopsy showing atypical hyperplasia.Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 oryounger; or One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, age at menarche 11 or less and age at first live birth 20 or more.Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 orolder and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at firstlive birth 30 or more.Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first livebirth 20 or older.Age 60 or older and: 5-year predicted risk of breast cancer â¥ 1.67%, as calculated by the Gail Model.For women whose risk factors are not described in the above examples, the Gail Model isnecessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a GailModel Risk Assessment Tool by dialing 1-800-544-2007.There are insufficient data available regarding the effect of NOLVADEX on breast cancerincidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specificrecommendations on the effectiveness of NOLVADEX in these patients.After an assessment of the risk of developing breast cancer, the decision regarding therapy withNOLVADEX for the reduction in breast cancer incidence should be based upon an individualassessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial,NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up periodof the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICALPHARMACOLOGY). DrugBank Targets: ¹⁶ 1. Estrogen receptor;2. Estrogen receptor beta;3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;4. Protein kinase C Mechanism of Action: ¹⁸ Target: estrogen receptors Action: competitor with estraidiol FDA: NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties inanimal test systems. The antiestrogenic effects may be related to its ability to compete withestrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of ratmammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression ofalready established DMBA-induced tumors. In this rat model, tamoxifen appears to exert itsantitumor effects by binding the estrogen receptors.In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol forestrogen receptor protein.

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ropivacaine

Approved

Phase 4

84057-95-4

175805 71273

Dimethyl fumarate

Approved, Investigational

Phase 4

624-49-7

637568 5271565

Immunologic Factors

Phase 4,Phase 3,Phase 2

Dermatologic Agents

Phase 4,Phase 2

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4

Antibodies

Phase 4,Phase 2

Immunoglobulins

Phase 4,Phase 2

Vaccines

Phase 4

Levoleucovorin

Approved, Investigational

Phase 3

68538-85-2

Fluorouracil

Approved

Phase 3

51-21-8

3385

leucovorin

Approved

Phase 3,Phase 2

58-05-9

6006 143

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2

59-30-3

6037

Protective Agents

Phase 3,Phase 2

Trace Elements

Phase 2, Phase 3,Phase 3

Micronutrients

Phase 2, Phase 3,Phase 3

Anthelmintics

Phase 3

Antiparasitic Agents

Phase 3

Adjuvants, Immunologic

Phase 3

Vitamin B9

Phase 3,Phase 2

Anti-Infective Agents

Phase 3,Phase 2

Vitamins

Phase 3

Antimetabolites

Phase 3,Phase 2

Antirheumatic Agents

Phase 3,Phase 2

Antidotes

Phase 3

Folate

Phase 3,Phase 2

Antimetabolites, Antineoplastic

Phase 3,Phase 2

Calcium, Dietary

Phase 3

Vitamin B Complex

Phase 3,Phase 2

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

6741

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

5755

Bupropion

Approved

Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 2

51-61-6, 62-31-7

681

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Cisplatin

Approved

Phase 2

15663-27-1

2767 441203 84093

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

446556 60843

Tacrolimus

Approved, Investigational

Phase 2

104987-11-3

445643 439492

Promethazine

Approved, Investigational

Phase 2

60-87-7

4927

Loratadine

Approved, Investigational

Phase 2

79794-75-5

3957

Histamine

Approved, Investigational

Phase 2

51-45-6, 75614-87-8

774

Acetaminophen

Approved

Phase 2

103-90-2

1983

Diphenhydramine

Approved, Investigational

Phase 2

147-24-0, 58-73-1

3100

Infliximab

Approved

Phase 2

170277-31-3

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Mycophenolic acid

Approved

Phase 2

24280-93-1

446541

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

46835353 6436030 5284616

Cyclophosphamide

Approved, Investigational

Phase 2

6055-19-2, 50-18-0

2907

Interventional clinical trials:

(show all 27)

#	Name	Status	NCT ID	Phase	Drugs
1	Pre-emptive Sciatic Bloc to Prevent Lower Limb Phantom Pain	Completed	NCT00528463	Phase 4
2	Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany	Completed	NCT02125604	Phase 4	dimethyl fumarate
3	Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels	Recruiting	NCT02637583	Phase 4	PCV13;PPV23
4	Community-based Follow-up of Severely Malnourished Children	Completed	NCT01157741	Phase 2, Phase 3
5	CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study	Completed	NCT01948856	Phase 3	J022X ST;Placebo
6	SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed	Completed	NCT00002551	Phase 3	fluorouracil;leucovorin calcium;levamisole hydrochloride
7	A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.	Unknown status	NCT02160132	Phase 2	Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
8	Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy	Completed	NCT01286402	Phase 2	Bupropion SR
9	GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer	Completed	NCT00068588	Phase 2	capecitabine
10	Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases	Completed	NCT01578668	Phase 2	erlotinib;pemetrexed;cisplatin;erlotinib
11	Effects of Inhibiting Early Inflammation in Kidney Transplant Patients	Recruiting	NCT02495077	Phase 2	Methylprednisolone;Mycophenolate Mofetil;Tacrolimus;Acetaminophen;Loratadine;Prednisone;Diphenhydramine
12	Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant	Active, not recruiting	NCT00305682	Phase 2	cyclophosphamide;Fludarabine;mycophenolate mofetil;Sirolimus
13	Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B	Not yet recruiting	NCT03519360	Phase 2
14	Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A	Not yet recruiting	NCT03519347	Phase 2
15	Ph I SU011248 + Irinotecan in Treatment of Pts w MG	Completed	NCT00611728	Phase 1	SU011248 & Irinotecan
16	ECALMIST Versus InSurE in Preterm Infant < 32 Weeks,Multicenter, Multinational RCT	Unknown status	NCT01848262	Not Applicable
17	Role of Cord Blood Hormones and Epinephrine in the Development of Transient Tachypnea of the Newborn	Completed	NCT01149928
18	Baby Observational and Nutritional Study	Completed	NCT01424696
19	Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow	Completed	NCT01544712	Not Applicable
20	Effects of Carotid Stent Design on Cerebral Embolization	Completed	NCT00830232	Not Applicable
21	Reproducibility Study of Transcranial Doppler	Completed	NCT03050567
22	Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors	Completed	NCT00872677
23	LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)	Recruiting	NCT03593395	Not Applicable
24	Systematic Screening for Comorbid Psychological Conditions in Cardiac ACSC Patients With Multimorbidity in the ED	Recruiting	NCT03188861
25	Blood Markers of Early Pancreas Cancer	Recruiting	NCT03568630
26	Foot Assessment in People With Diabetes: A Quantitative Diagnostic Approach	Recruiting	NCT03089463
27	Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies	Not yet recruiting	NCT03762733

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Sources

Genetic Tests for Suppressor of Tumorigenicity 3

Sources

Anatomical Context for Suppressor of Tumorigenicity 3

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

⁴¹

Cervix, Lymph Node, Endothelial, Testes, B Cells, Bone, Breast

Sources

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 1427)

#	Title	Authors	Year
1	Suicide Gene Therapy of Oral Squamous Cell Carcinoma and Cervical Carcinoma In Vitro. ( 30539538 )	D?zg?ne? N...Konopka K	2019
2	Genomic Network-Based Analysis Reveals Pancreatic Adenocarcinoma Up-Regulating Factor-Related Prognostic Markers in Cervical Carcinoma. ( 30406031 )	Kim J...Hewitt SM	2018
3	Endometrial cancer after radiation therapy for cervical carcinoma: A radiological approach. ( 30017294 )	Lopes J...Cunha TM	2018
4	DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma. ( 29859790 )	Simonsen TG...Rofstad EK	2018
5	Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles. ( 30428576 )	Xia Y...Zhu B	2018
6	Dosimetric research into target regions and organs at risk in three-dimensional intracavitary brachytherapy techniques for Chinese patients with cervical carcinoma. ( 30452658 )	Wu N...Zhao H	2018
7	Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy (3DCRT) and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma. ( 30452664 )	Dracham CB...Ghoshal S	2018
8	Effects of forkhead Box protein A1 on cell proliferation regulating and EMT of cervical carcinoma. ( 30468461 )	Gu F...Yan ZM	2018
9	A ruthenium(II) complex containing a p-cresol group induces apoptosis in human cervical carcinoma cells through endoplasmic reticulum stress and reactive oxygen species production. ( 30508750 )	Xu L...Chao H	2018
10	Intralesional and subcutaneous application of Viscum album L. (European mistletoe) extract in cervical carcinoma in situ: A CARE compliant case report. ( 30508950 )	Reynel M...Kienle GS	2018
11	Association between Epstein-Barr virus (EBV) and cervical carcinoma: A meta-analysis. ( 29021084 )	de Lima MAP...Lima MVA	2018
12	Activation of Wnt-β-catenin pathway in basal-parabasal layers of normal cervical epithelium comparable during development of uterine cervical carcinoma. ( 29079964 )	Chakraborty C...Panda CK	2018
13	Squamous cell carcinoma antigen, platelet distribution width, and prealbumin collectively as a marker of squamous cell cervical carcinoma. ( 29103023 )	Fu S...Wang RT	2018
14	The antitumor effect of folic acid conjugated-Auricularia auricular polysaccharide-cisplatin complex on cervical carcinoma cells in nude mice. ( 29132812 )	Qiu J...Geng L	2018
15	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. ( 29145543 )	Lheureux S...Oza AM	2018
16	Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. ( 29182608 )	Seamon LG...Tewari KS	2018
17	Photo-triggered destabilization of nanoscopic vehicles by dihydroindolizine for enhanced anticancer drug delivery in cervical carcinoma. ( 29195229 )	Singh P...Pal SK	2018
18	Intravoxel incoherent motion MR imaging of early cervical carcinoma: correlation between imaging parameters and tumor-stroma ratio. ( 29222676 )	Li X...Yu T	2018
19	CDH1 promoter methylation in patients with cervical carcinoma: a systematic meta-analysis with trial sequential analysis. ( 29237293 )	Liu G	2018
20	RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis. ( 29288321 )	Zheng F...Yu H	2018
21	Positron emission tomography-magnetic resonance imaging (PET-MRI) for response assessment after radiation therapy of cervical carcinoma: a pilot study. ( 29292485 )	Mongula JE...Slangen BFM	2018
22	The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma. ( 29297234 )	Lee SY...Cho DH	2018
23	Predicting Parametrial Invasion in Cervical Carcinoma (Stages IB1, IB2, and IIA): Diagnostic Accuracy of T2-Weighted Imaging Combined With DWI at 3 T. ( 29323549 )	Qu JR...Li HL	2018
24	Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions. ( 29324535 )	Morkel M...Simonds H	2018
25	Quercetin and aconitine synergistically induces the human cervical carcinoma HeLa cell apoptosis via endoplasmic reticulum (ER) stress pathway. ( 29324796 )	Li XM...Yang PL	2018
26	Prognostic Value of Volume-Based Metabolic Parameters Obtained by 18F-FDG-PET/CT in Patients With Locally Advanced Squamous Cell Cervical Carcinoma. ( 29369948 )	Liang Y...Wu N	2018
27	Effect of Ku80 on the radiosensitization of cisplatin in the cervical carcinoma cell line HeLa. ( 29375707 )	Zhuang L...Huang X	2018
28	Anticancer activity of crocin against cervical carcinoma (HeLa cells): Bioassessment and toxicity evaluation of crocin in male albino rats. ( 29413694 )	Jiang Z...Zhang Y	2018
29	The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth. ( 29416779 )	Xu L...Xu J	2018
30	Expression of the cervical carcinoma expressed PCNA regulatory (CCEPR) long noncoding RNA is driven by the human papillomavirus E6 protein and modulates cell proliferation independent of PCNA. ( 29427865 )	Sharma S...Munger K	2018
31	Methylation of the L1 gene and integration of human papillomavirus 16 and 18 in cervical carcinoma and premalignant lesions. ( 29434935 )	Torres-Rojas FI...Illades-Aguiar B	2018
32	The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma. ( 29434970 )	A Y...Zhao S	2018
33	microRNA-136 inhibits proliferation and promotes apoptosis and radiosensitivity of cervical carcinoma through the NF-κB pathway by targeting E2F1. ( 29452167 )	Lu HJ...Zheng YL	2018
34	[18F]FDG-PET/CT and MRI for initial pelvic lymph node staging in patients with cervical carcinoma: The potential usefulness of [18F]FDG-PET/MRI. ( 29467905 )	Anner P...Karanikas G	2018
35	RBBP6 promotes human cervical carcinoma malignancy via JNK signaling pathway. ( 29501043 )	Teng F...Gao LJ	2018
36	MicroRNA-409 inhibits the proliferative ability of cervical carcinoma cells by regulating AKT. ( 29509241 )	Li B...Shang LX	2018
37	Laparoscopic laterally extended endopelvic resection (LEER) for cervical carcinoma recurring at the pelvic sidewall after concurrent chemoradiotherapy: Our experience in three cases. ( 29510867 )	Kanao H...Takeshima N	2018
38	Prognostic Significance of Vascular Endothelial Growth Factor (VEGF) and Her-2 Protein in the Genesis of Cervical Carcinoma. ( 29531585 )	Rahmani AH...Husain NEOS	2018
39	MicroRNA-21-5p induces the metastatic phenotype of human cervical carcinoma cells in vitro by targeting the von Hippel-Lindau tumor suppressor. ( 29552160 )	Cai L...Wu S	2018
40	Induction of apoptosis in human cervical carcinoma HeLa cells by active compounds from Hypericum ascyron L. ( 29556280 )	Li XM...Zhang TC	2018
41	The in vitro effects of a novel estradiol analog on cell proliferation and morphology in human epithelial cervical carcinoma. ( 29568313 )	Boyd LS...Joubert AM	2018
42	Effect of Curcumin-Nanoemulsion Associated with Photodynamic Therapy in Cervical Carcinoma Cell Lines. ( 29581972 )	de Matos RPA...Rahal P	2018
43	Mitofusin-2 Triggers Cervical Carcinoma Cell Hela Apoptosis via Mitochondrial Pathway in Mouse Model. ( 29587277 )	Wang W...Quan H	2018
44	Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience. ( 29595759 )	Castelnau-Marchand P...Chargari C	2018
45	TMC120 displayed potent cytotoxic effect on human cervical carcinoma through enhancing the polymerization of microtubules. ( 29596107 )	Shi L...Liu S	2018
46	Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. ( 29603728 )	Annunziata C...Tornesello ML	2018
47	The role of folic acid-conjugated polyglycerol coated iron oxide nanoparticles on radiosensitivity with clinical electron beam (6 MeV) on human cervical carcinoma cell line: In vitro study. ( 29626804 )	Fakhimikabir H...Rahgozar S	2018
48	Up-regulation of miR-20a by HPV16 E6 exerts growth-promoting effects by targeting PDCD6 in cervical carcinoma cells. ( 29710555 )	Liu X	2018
49	Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy. ( 29721161 )	Kaliff M...Lillsunde-Larsson G	2018
50	Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice. ( 29774117 )	Mertens B...Andrei G	2018

Sources

Genes for Suppressor of Tumorigenicity 3

Genes related to Suppressor of Tumorigenicity 3 (1 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	ST3	Suppression Of Tumorigenicity 3	Genetic Locus	50	Genetic linkage ⁵⁷
2	TP53	Tumor Protein P53	Protein Coding	19.24	Novoseek inferred ⁵⁵	10374328 10813720 10072870 (more) 8630877 9334921 10098748 15617346 11378660 11769670 19145674 11574134 8388491 17685229 8920796 1363512 8393371 11023067 8142262 8238255 12451999 9470836 14670624 11148563 9662253 10739702 8018409 8384745 1646990 17671528 9772303 16289387 10719811 8302581 10607922 9208900 12908520 17310826 1322242 8806692 10900010 9788606 9367711 13678722 7503188 7718254 8433212 8380785 1648361 9219832 8706159 8745488 8152158 1352566 12190289 11396132 8674562 9648588 19657726 18439073 10329038 19216720 17352217 16026074 1327506 17567683 15047823 10567656 20395210 1648218 8387205 12504622 17192686 15378004 15202785 14681700 12795334 12713987 12431761 12144687 15380586 7910219 8229452 8397367 8389030 1327751 19660100 19744917 15262117 10817508 10729761 10491526 9790785 9162297 8631546 8601524 17290384 17208232 15201979 15116093
3	FHIT	Fragile Histidine Triad	Protein Coding	18.52	Novoseek inferred ⁵⁵	15573771 9354423 19471558 (more) 16078573 10999736 12893195 14660280 10675384 10585575 17671528 11004671 11891319 9187105 12657123 11389064 10027335 18494825 12355215 9537577 10223242 18608185 9928473 9537583 16865265 9242443 11350899
4	RB1	RB Transcriptional Corepressor 1	Protein Coding	17.89	Novoseek inferred ⁵⁵	15617346 10329038 1648361 (more) 10393912 1668886 1316611 1322242 15767426 9772434 10491526 15575375 11004671 11503038 11161855 14506250 1309779 10082538
5	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	17.5	Novoseek inferred ⁵⁵	12948409 17359536 15730957 (more) 9648588 12911724 9698478 16027780 17697601 17521451 20112504 16259056 16633070 20432728 19851197 18365017 11448914 18722107 19256750 19142477 18301453 15575375 8821952 19514374 17672936 19100258 16494930 19145204 9159345 10535995 9166931 16677523 16415792
6	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	17.04	Novoseek inferred ⁵⁵	12948409 8414499 1619315 (more) 9648593 14729369 15491757 9673366 15585135 10583438 9891436 8289968 10082554 8519685 11134351 7641187 11803460 1721614 9291819 1326470
7	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	16.66	Novoseek inferred ⁵⁵	19657726 9568185 11179504 (more) 10329038 16026074 18425078 19935879 12795334 11956602 17685229 9524287 11595134 1707025 12392301 16677523
8	UBE3A	Ubiquitin Protein Ligase E3A	Protein Coding	16.66	Novoseek inferred ⁵⁵	8397367 15731267
9	BCL2	BCL2, Apoptosis Regulator	Protein Coding	16.56	Novoseek inferred ⁵⁵	11769670 18788571 9465813 (more) 7768985 9059353 11809111 17464868 10618615 15889622 10739702 9703806 9808425 8691340 12504622 10037278 9655299 19362787 14558950 15899779 11956602 17713095 9162297 9421084 11775218 12440815 15201979 15380586 15917408
10	TAP1	Transporter 1, ATP Binding Cassette Subfamily B Member	Protein Coding	16.47	Novoseek inferred ⁵⁵	8270878 11713591 17382375 (more) 19263211 8198988 17622526 17366619 7640226 19202550
11	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	16.25	Novoseek inferred ⁵⁵	10618615 15889622 9703806 (more) 9808425 9655299 15380586 11606099 9274913 10391567 15917408
12	CCNB1	Cyclin B1	Protein Coding	16.18	Novoseek inferred ⁵⁵	10741643 16614707
13	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	16.04	Novoseek inferred ⁵⁵	15617346 11593543 8774650 (more) 9790789 11082996 11925126 7718254

Sources

Variations for Suppressor of Tumorigenicity 3

Sources

Expression for Suppressor of Tumorigenicity 3

Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.

Sources

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 80)

#	Super pathways	Score	Top Affiliating Genes
1	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.7	BCL2 CCNB1 CDKN1A CDKN2A MYC RB1
2	Cell Cycle, Mitotic ⁶⁶ Show member pathways Cell Cycle ⁶⁶ M Phase ⁶⁶	13.43	CCNB1 CDKN1A CDKN2A MYC PCNA RB1
3	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	13.05	BAX BCL2 CDKN1A MYC RB1 TP53
4	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	13	BAX CCNB1 CDKN1A CDKN2A PCNA TP53
5	Human cytomegalovirus infection ³⁷ Show member pathways Hepatitis B ³⁷ Human immunodeficiency virus 1 infection ³⁷ Kaposi sarcoma-associated herpesvirus infection ³⁷	12.99	BAX BCL2 CCNB1 CDKN1A CDKN2A MYC
6	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ DR3 Signaling ⁶⁴ Fas Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.93	BAX BCL2 CDKN1A RB1 TP53
7	Pathways in cancer ³⁷	12.91	BAX BCL2 CDKN1A CDKN2A MYC RB1
8	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.89	BAX BCL2 CDKN1A CDKN2A MYC PCNA
9	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ¹ Apoptosis ³⁷ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁵ Death Receptor Signaling ⁶⁷	12.86	BAX BCL2 CDKN1A CDKN2A MYC TP53
10	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.84	BAX BCL2 CDKN1A CDKN2A FHIT RB1
11	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.83	BAX BCL2 CDKN1A CDKN2A MYC RB1
12	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.72	BAX BCL2 CCNB1 CDKN1A MYC PCNA
13	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.65	BAX BCL2 RB1 TP53
14	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.64	BAX BCL2 CDKN1A MYC TP53
15	Mitotic G1-G1/S phases ⁶⁶ Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶⁶	12.62	CCNB1 CDKN1A CDKN2A MYC PCNA RB1
16	DNA Damage ⁴	12.6	CCNB1 CDKN1A CDKN2A PCNA RB1 TP53
17	MicroRNAs in cancer ³⁷	12.57	BCL2 CDKN1A CDKN2A MYC TP53
18	Human T-cell leukemia virus 1 infection ³⁷	12.49	BAX CDKN1A CDKN2A MYC PCNA RB1
19	Development IGF-1 receptor signaling ²² Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.47	BAX CDKN1A MYC PCNA TP53
20	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ Cyclin D associated events in G1 ⁶⁶ G1 Phase ⁶⁶ G1-S Phase Transition ⁶⁴ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes ⁶⁶	12.42	CCNB1 CDKN1A CDKN2A RB1 TP53
21	Viral carcinogenesis ³⁷	12.39	BAX CDKN1A CDKN2A RB1 TP53 UBE3A
22	Cell cycle ¹ ³⁷	12.38	CCNB1 CDKN1A CDKN2A MYC PCNA RB1
23	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.34	BAX BCL2 CDKN1A RB1 TP53
24	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.3	BAX BCL2 CDKN1A MYC RB1 TP53
25	Epstein-Barr virus infection ³⁷	12.3	BAX BCL2 CDKN1A MYC RB1 TAP1
26	Transcriptional misregulation in cancer ³⁷	12.29	BAX CDKN1A MYC TP53
27	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.29	BAX BCL2 CCNB1 CDKN1A CDKN2A MYC
28	Cell cycle Role of SCF complex in cell cycle regulation ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Regulation of G1/S transition (part 1) ²² Immune response MIF-JAB1 signaling ²²	12.26	CDKN1A CDKN2A MYC RB1
29	Cellular senescence (KEGG) ³⁷	12.25	CCNB1 CDKN1A CDKN2A MYC RB1 TP53
30	Integrated Breast Cancer Pathway ¹	12.24	BAX BCL2 MYC RB1 TP53
31	Colorectal Cancer Metastasis ⁶⁴	12.23	BAX CDKN1A MYC TP53
32	AKT Signaling Pathway ⁶⁷	12.22	BAX BCL2 CDKN1A MYC TP53
33	SMAD Signaling Network ⁶⁴	12.14	BCL2 CDKN1A CDKN2A RB1 TP53 UBE3A
34	NGF Pathway ⁶⁴ Show member pathways TRKA Signaling ⁶⁴	12.11	BAX MYC TP53
35	Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling ⁶⁵ Show member pathways Basal cell carcinoma ³⁷	12.11	BAX CDKN1A TP53
36	Glioblastoma Multiforme ⁶⁴	12.09	CDKN1A CDKN2A MYC RB1 TP53
37	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	12.06	BAX BCL2 CDKN1A MYC
38	DNA Damage Response (only ATM dependent) ¹	12.06	BAX BCL2 CDKN1A CDKN2A MYC TP53
39	TGF-beta Signaling Pathway (WikiPathways) ¹	12.05	CDKN1A MYC TP53
40	Interleukin-4 and 13 signaling ⁶⁶	12.05	BCL2 CDKN1A MYC TP53
41	Cell cycle Cell cycle (generic schema) ²² Show member pathways Cell cycle Regulation of G1/S transition (part 2) ²² G0 and Early G1 ⁶⁶ G2 Phase ⁶⁶	12.03	CCNB1 MYC PCNA RB1 TP53
42	TP53 Regulates Transcription of Cell Cycle Genes ⁶⁶ Show member pathways TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain ⁶⁶ TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest ⁶⁶ TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest ⁶⁶	12.03	BAX CCNB1 CDKN1A PCNA TP53
43	Activation of BH3-only proteins ⁶⁶ Show member pathways Activation of BAD and translocation to mitochondria ⁶⁶ Activation of BIM and translocation to mitochondria ⁶⁶ Activation of BMF and translocation to mitochondria ⁶⁶ Activation of NOXA and translocation to mitochondria ⁶⁶ Activation of PUMA and translocation to mitochondria ⁶⁶ Activation, myristolyation of BID and translocation to mitochondria ⁶⁶ BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members ⁶⁶ Intrinsic Pathway for Apoptosis ⁶⁶	12.02	BAX BCL2 TP53
44	Spinal Cord Injury ¹	12	MYC RB1 TP53
45	Senescence and Autophagy in Cancer ¹	12	BCL2 CDKN1A CDKN2A PCNA RB1 TP53
46	Sphingolipid signaling pathway ³⁷	11.99	BAX BCL2 TP53
47	Amyotrophic lateral sclerosis (ALS) ¹ ³⁷ Show member pathways Pathogenesis of ALS ⁶⁴	11.97	BAX BCL2 TP53
48	Validated targets of C-MYC transcriptional activation ¹	11.89	BAX CCNB1 MYC TP53
49	Androgen receptor signaling pathway ¹	11.87	CDKN1A RB1 UBE3A
50	C-MYB transcription factor network ¹	11.87	BCL2 CCNB1 CDKN1A MYC

Sources

GO Terms for Suppressor of Tumorigenicity 3

Cellular components related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	9.9	BAX BCL2 CCNB1 CDKN1A CDKN2A FHIT
2	nucleoplasm	GO:0005654	9.86	BCL2 CCNB1 CDKN1A CDKN2A MYC PCNA
3	pore complex	GO:0046930	8.96	BAX BCL2
4	PCNA-p21 complex	GO:0070557	8.62	CDKN1A PCNA

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 47)

#	Name	GO ID	Score	Top Affiliating Genes
1	response to drug	GO:0042493	9.97	BCL2 CCNB1 CDKN1A MYC
2	cytokine-mediated signaling pathway	GO:0019221	9.96	BCL2 CDKN1A MYC TP53
3	cellular response to DNA damage stimulus	GO:0006974	9.95	BAX BCL2 CDKN1A MYC PCNA TP53
4	viral process	GO:0016032	9.93	BAX PCNA RB1 TAP1 TP53 UBE3A
5	regulation of cell cycle	GO:0051726	9.91	BAX BCL2 CCNB1 RB1
6	negative regulation of cell proliferation	GO:0008285	9.91	BAX BCL2 CDKN1A CDKN2A RB1 TP53
7	cellular response to hypoxia	GO:0071456	9.86	BCL2 CCNB1 MYC TP53
8	negative regulation of cell growth	GO:0030308	9.85	BCL2 CDKN1A CDKN2A TP53
9	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.81	BCL2 CDKN1A RB1
10	positive regulation of fibroblast proliferation	GO:0048146	9.81	CCNB1 CDKN1A MYC
11	response to toxic substance	GO:0009636	9.81	BAX BCL2 CCNB1 CDKN1A
12	regulation of mitotic cell cycle	GO:0007346	9.8	CDKN1A MYC RB1
13	G1/S transition of mitotic cell cycle	GO:0000082	9.8	CDKN1A CDKN2A MYC RB1
14	neuron apoptotic process	GO:0051402	9.79	BAX BCL2 RB1
15	positive regulation of intrinsic apoptotic signaling pathway	GO:2001244	9.78	BAX BCL2 TP53
16	negative regulation of fibroblast proliferation	GO:0048147	9.77	BAX MYC TP53
17	intrinsic apoptotic signaling pathway	GO:0097193	9.76	BAX CDKN1A TP53
18	intrinsic apoptotic signaling pathway by p53 class mediator	GO:0072332	9.71	BAX FHIT TP53
19	negative regulation of cyclin-dependent protein serine/threonine kinase activity	GO:0045736	9.7	CDKN1A CDKN2A
20	negative regulation of apoptotic signaling pathway	GO:2001234	9.7	BAX BCL2
21	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	GO:1900740	9.7	BCL2 TP53
22	apoptotic mitochondrial changes	GO:0008637	9.7	BAX BCL2 CDKN2A
23	cellular senescence	GO:0090398	9.69	CDKN1A CDKN2A
24	B cell homeostasis	GO:0001782	9.69	BAX BCL2
25	release of cytochrome c from mitochondria	GO:0001836	9.69	BAX BCL2
26	positive regulation of smooth muscle cell migration	GO:0014911	9.68	BCL2 MYC
27	negative regulation of phosphorylation	GO:0042326	9.68	CDKN1A CDKN2A
28	positive regulation of protein oligomerization	GO:0032461	9.68	BAX TP53
29	endoplasmic reticulum calcium ion homeostasis	GO:0032469	9.68	BAX BCL2
30	hypothalamus development	GO:0021854	9.67	BAX MYC
31	regulation of mitochondrial membrane permeability	GO:0046902	9.67	BCL2 TP53
32	Ras protein signal transduction	GO:0007265	9.67	CDKN1A CDKN2A RB1 TP53
33	regulation of protein heterodimerization activity	GO:0043497	9.66	BAX BCL2
34	regulation of protein homodimerization activity	GO:0043496	9.65	BAX BCL2
35	leukocyte homeostasis	GO:0001776	9.65	BAX BCL2
36	cell cycle arrest	GO:0007050	9.65	CDKN1A CDKN2A MYC RB1 TP53
37	signal transduction by p53 class mediator	GO:0072331	9.64	CDKN1A TP53
38	cellular response to UV	GO:0034644	9.62	BAX MYC PCNA TP53
39	positive regulation of developmental pigmentation	GO:0048087	9.58	BAX BCL2
40	replicative senescence	GO:0090399	9.58	CDKN1A CDKN2A TP53
41	regulation of nitrogen utilization	GO:0006808	9.57	BAX BCL2
42	ovarian follicle development	GO:0001541	9.46	BAX BCL2 MYC UBE3A
43	response to gamma radiation	GO:0010332	9.26	BAX BCL2 MYC TP53
44	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.02	BAX CCNB1 CDKN1A PCNA TP53
45	apoptotic process	GO:0006915	10.08	BAX BCL2 CDKN2A FHIT RB1 TP53
46	cell cycle	GO:0007049	10.06	CCNB1 CDKN1A CDKN2A RB1 TP53
47	cell proliferation	GO:0008283	10.02	BAX BCL2 MYC PCNA TP53

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.8	BAX BCL2 FHIT PCNA RB1 TP53
2	protein kinase binding	GO:0019901	9.73	CCNB1 CDKN1A CDKN2A TP53
3	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	9.37	CDKN1A CDKN2A
4	transcription factor binding	GO:0008134	9.35	BCL2 CDKN2A MYC RB1 TP53
5	disordered domain specific binding	GO:0097718	9.33	CDKN2A RB1 TP53
6	BH3 domain binding	GO:0051434	9.26	BAX BCL2
7	ubiquitin protein ligase binding	GO:0031625	9.02	BCL2 CDKN1A FHIT RB1 TP53
8	protein binding	GO:0005515	10.18	BAX BCL2 CCNB1 CDKN1A CDKN2A FHIT

Sources

Sources for Suppressor of Tumorigenicity 3

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Suppressor of Tumorigenicity 3 (ST3)

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Classifications:

External Ids:

Summaries for Suppressor of Tumorigenicity 3

Related Diseases for Suppressor of Tumorigenicity 3

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM:

GenomeRNAi Phenotypes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

FDA approved drugs:

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Suppressor of Tumorigenicity 3

Anatomical Context for Suppressor of Tumorigenicity 3

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

Genes for Suppressor of Tumorigenicity 3

Genes related to Suppressor of Tumorigenicity 3 (1 elite genes):

Variations for Suppressor of Tumorigenicity 3

Expression for Suppressor of Tumorigenicity 3

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

GO Terms for Suppressor of Tumorigenicity 3

Cellular components related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

Sources for Suppressor of Tumorigenicity 3